Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) is now available.
Shandong Weigao Group Medical Polymer Company Limited has announced the proposed adoption of a 2025 H Share Incentive Scheme, aimed at attracting and retaining key contributors to the company’s long-term growth. The scheme is designed to align the interests of participants with those of the company and its shareholders, enhancing the company’s long-term remuneration strategy and overall performance. The adoption of this scheme is subject to shareholder approval at an upcoming extraordinary general meeting.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a joint stock limited company incorporated in the People’s Republic of China. The company operates in the medical polymer industry, focusing on the production and distribution of medical devices and related products. It aims to serve the healthcare sector with innovative solutions and has a strong market presence in China.
Average Trading Volume: 12,326,945
Technical Sentiment Signal: Hold
Current Market Cap: HK$30.89B
For detailed information about 1066 stock, go to TipRanks’ Stock Analysis page.